symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
CMPX,1.98,0.525592,246035,252368820,0,1.81-5.65,0.02,"Compass Therapeutics, Inc.",USD,0001738021,,20454B104,NASDAQ Capital Market,NASDAQ,Biotechnology,https://www.compasstherapeutics.com,"Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.","Dr. Thomas J. Schuetz M.D., Ph.D.",Healthcare,US,26,617 500 8099,80 Guest Street,Boston,MA,02135,,0,https://financialmodelingprep.com/image-stock/CMPX.png,2021-04-05,False,False,True,False,False
